Genprex receives Nasdaq delisting determination; plans to request hearing panel review
Genprex received a delisting determination from Nasdaq's Listing Qualifications Staff on June 10, 2026, after the company's common stock closed below the…
$1.0030 consecutive business daysJune 10, 2026